VITASPRING BIOMEDICAL CO., LTD.: common shares outstanding

What this measure means

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Exact concept: us-gaap:CommonStockSharesOutstanding. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-01-31 to 2026-01-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• VITASPRING BIOMEDICAL CO., LTD.: total assets
• VITASPRING BIOMEDICAL CO., LTD.: total liabilities
• VITASPRING BIOMEDICAL CO., LTD.: stockholders equity
• VITASPRING BIOMEDICAL CO., LTD.: cash and cash equivalents
• VITASPRING BIOMEDICAL CO., LTD.: net income or loss
• VITASPRING BIOMEDICAL CO., LTD.: operating cash flow
• VITASPRING BIOMEDICAL CO., LTD.: revenue
• VITASPRING BIOMEDICAL CO., LTD.: financing cash flow
• VITASPRING BIOMEDICAL CO., LTD.: investing cash flow
• VITASPRING BIOMEDICAL CO., LTD.: retained earnings or deficit
• VITASPRING BIOMEDICAL CO., LTD.: diluted weighted-average shares
• VITASPRING BIOMEDICAL CO., LTD.: diluted earnings per share
• VITASPRING BIOMEDICAL CO., LTD.: income tax expense or benefit
• VITASPRING BIOMEDICAL CO., LTD.: net property, plant and equipment
• VITASPRING BIOMEDICAL CO., LTD.: share-based compensation expense
• VITASPRING BIOMEDICAL CO., LTD.: operating income or loss
• VITASPRING BIOMEDICAL CO., LTD.: current assets
• VITASPRING BIOMEDICAL CO., LTD.: current liabilities
• VITASPRING BIOMEDICAL CO., LTD.: current accounts payable
• VITASPRING BIOMEDICAL CO., LTD.: net current accounts receivable
• VITASPRING BIOMEDICAL CO., LTD.: operating expenses
• VITASPRING BIOMEDICAL CO., LTD.: net inventory
• VITASPRING BIOMEDICAL CO., LTD.: gross profit
• VITASPRING BIOMEDICAL CO., LTD.: selling, general and administrative expense
• VITASPRING BIOMEDICAL CO., LTD.: cash including restricted cash
• VITASPRING BIOMEDICAL CO., LTD.: additional paid-in capital
• VITASPRING BIOMEDICAL CO., LTD.: total equity including noncontrolling interests
• VITASPRING BIOMEDICAL CO., LTD.: operating lease right-of-use asset
• VITASPRING BIOMEDICAL CO., LTD.: operating lease liability
• VITASPRING BIOMEDICAL CO., LTD.: accumulated depreciation on property, plant and equipment
• VITASPRING BIOMEDICAL CO., LTD.: net deferred tax assets
• VITASPRING BIOMEDICAL CO., LTD.: pre-tax income or loss from continuing operations
• VITASPRING BIOMEDICAL CO., LTD.: profit or loss including noncontrolling interests
• VITASPRING BIOMEDICAL CO., LTD.: general and administrative expense
• VITASPRING BIOMEDICAL CO., LTD.: depreciation expense
• VITASPRING BIOMEDICAL CO., LTD.: other nonoperating income or expense
• VITASPRING BIOMEDICAL CO., LTD.: current income tax expense or benefit
• VITASPRING BIOMEDICAL CO., LTD.: deferred income tax expense or benefit
• VITASPRING BIOMEDICAL CO., LTD.: income taxes paid, net
• VITASPRING BIOMEDICAL CO., LTD.: proceeds from issuing common stock
• VITASPRING BIOMEDICAL CO., LTD.: operating lease payments
• VITASPRING BIOMEDICAL CO., LTD.: change in accounts receivable
• VITASPRING BIOMEDICAL CO., LTD.: change in inventories
• VITASPRING BIOMEDICAL CO., LTD.: change in accounts payable

Inspect the source

Entity

VITASPRING BIOMEDICAL CO., LTD. / CIK 0001697884

Captured

2026-09-21T17:23:44.772Z

SEC response SHA-256

ee15de6dda3aedafc6c6b7ee7d9d21edb5e0091bf01dcbaec55b3fe460e6f43a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001697884.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))